Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLINDAMYCIN PHOSPHATE

All injection strengths: not a benefit

Other products in the same Health Canada class (J01FF) — coverage varies; not interchangeable

  • Clindamycin (Dalacin C): general benefit, Not a benefit
  • Clindamycin palmitate (Dalacin C Flavoured Granules): general benefit

Clindamycin Phosphate Injection USP · DIN 02230540 · 300mg/2mL · injection solution-2mL Pk

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clindamycin Phosphate Injection USP · DIN 02230540 Manufacturer: Sandoz Canada Inc.; listing date 2001-03-07 Health Canada: Marketed since 2005-08-26 · brand CLINDAMYCIN INJECTION USP · ATC J01FF01 CLINDAMYCIN · form Liquid · route Intravenous, Intramuscular · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Clindamycin Phosphate Injection USP: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49612 · Verify on the e-Formulary ↗ (DIN 02230540)

Source record
DIN 02230540: Clindamycin Phosphate Injection USP Raw flags: notABenefit=Y, sec3=Y Item: 081228008; group id 46; item number 0103; lccId None; manufacturer id SDZ Source form: Inj Sol-2mL Pk; strength: 300mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230540 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49612 Therapeutic Notes (formulary) Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.
Interchangeable products
Dalacin C · DIN 00260436 · $8.8938
Shortage status: resolved shortage (ended 2023-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230540
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, gynecological infections, intra-abdominal infections, septicemia, skin and skin structure infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 2 - Gynecological infections such as endometritis and pelvic cellulitis PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 3 - Septicemia PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 6 - Bone and joint infections caused by Staphylococcus aureus PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications Clindamycin Injection USP (clindamycin phosphate) is indicated for the treatment of serious infections due to susceptible anaerobic bacteria, such as Bacteroides species, Peptostreptococcus, anaerobic streptococci, Clostridium species and microaerophilic streptococci. Clindamycin Injection USP is also indicated for the treatment of serious infections due to susceptible strains of gram positive aerobic bacteria (staphylococci, including penicillinase- producing staphylococci, streptococci and pneumococci) as well as in the treatment of Chlamydia trachomatis, when the patient is intolerant of, or the organism is resistant to other appropriate antibiotics. Because of the risk of Clostridium difficile-associated disease (CDAD) as described in 7 Warnings and Precautions, before selecting clindamycin the healthcare professional should consider the nature of the infection and the suitability of alternative therapy. Clindamycin Injection USP is indicated for the treatment of the following serious infections when caused by susceptible strains of the designated organisms in the conditions listed below: • Lower respiratory infections including pneumonia, empyema… https://pdf.hres.ca/dpd_pm/00085906.PDF PM date: AUG 27, 2026 Source product: CLINDAMYCIN INJECTION USP; DIN 02230540; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Clindamycin Phosphate Injection USP: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026